The role of N-acetylcysteine in the management of acute and chronic pulmonary complications of sulfur mustard: A literature review

Inhalation Toxicology

Volumn 26, Issue 9, 2014, Pages 507-523

  Shohrati, Majid ^a   Karimzadeh, Iman ^b   Saburi, Amin ^a   Khalili, Hossein ^b   Ghanei, Mostafa ^a  

^a BAQIYATALLAH UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Acetylcysteine; Early lung injuries; Late lung injuries; Mustard gas; Prophylaxis; Treatment

Indexed keywords

ACETYLCYSTEINE; CHLORMETHINE; CLARITHROMYCIN; DIMETHYLTHIOUREA; DOXYCYCLINE; METHENAMINE; MUSTARD GAS; NICOTINAMIDE; CHEMICAL WARFARE AGENT;

ACUTE LUNG INJURY; APOPTOSIS; BRONCHIOLITIS OBLITERANS; CHEMOPROPHYLAXIS; CHRONIC LUNG DISEASE; CHRONOTHERAPY; CYTOTOXICITY; DRUG EFFICACY; EMBASE; ENVIRONMENTAL EXPOSURE; HUMAN; IN VITRO STUDY; INFLAMMATION; LUNG ALVEOLUS CELL; LUNG TOXICITY; MEDLINE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; ANIMAL; CHEMICALLY INDUCED; DISEASE MODEL; DRUG EFFECTS; LUNG; TOXICITY;

ACETYLCYSTEINE; ANIMALS; BRONCHIOLITIS OBLITERANS; CHEMICAL WARFARE AGENTS; DISEASE MODELS, ANIMAL; HUMANS; LUNG; MUSTARD GAS; OXIDATIVE STRESS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84904871496     PISSN: 08958378     EISSN: 10917691     Source Type: Journal    
DOI: 10.3109/08958378.2014.920439     Document Type: Review

References (92)

1. Afaq F, Abidi P, Rahman Q. (2000). N-acetyl L-cysteine attenuates oxidant-mediated toxicity induced by chrysotile fibers. Toxicol Lett 117:53-60.
2. Aitio ML. (2006). N-acetylcysteine - passe-partout or much ado about nothing? Br J Clin Pharmacol 61:5-15.
3. Akdur O, Sozuer EM, Ikizceli I, et al. (2008). Experimental inhalation of chlorine gas produced with a different method: effects of N-acetyl cysteine on acute pulmonary damage. Toxicol Mech Methods 18: 739-43.
4. Allon N, Amir A, Manisterski E, et al. (2009). Inhalation exposure to sulfur mustard in the guinea pig model: clinical, biochemical and histopathological characterization of respiratory injuries. Toxicol Appl Pharmacol 241:154-62.
5. Alsop JA. (2012). Managing drug overdoses and poisonings. In: Alldredge BK, Corelli RL, Ernst ME, et al. (eds.) Koda- applied therapeutics: the clinical use of drugs. Philadelphia, PA: Lippincott Williams & Wilkins, 85.
6. Altenburg J, de Graaff CS, van der Werf TS, Boersma WG. (2011). Immunomodulatory effects of macrolide antibiotics - part 2: advantages and disadvantages of long-term, low-dose macrolide therapy. Respiration 81:75-87.
7. Anderson DR, Byers SL, Vesely KR. (2000). Treatment of sulfur mustard (HD)-induced lung injury. J Appl Toxicol Suppl 1:S129-32.
8. Arfsten DP, Johnson EW, Wilfong ER, et al. (2007). Distribution of radio-labeled N-acetyl-L-cysteine in Sprague-Dawley rats and its effect on glutathione metabolism following single and repeat dosing by oral gavage. Cutan Ocul Toxicol 26:113-34.
9. Atkins KB, Lodhi IJ, Hurley LL, Hinshaw DB. (2000). N-acetylcysteine and endothelial cell injury by sulfur mustard. J Appl Toxicol 20: S125-8.
10. Atkuri KR, Mantovani JJ, Herzenberg LA, Herzenberg LA. (2007). NAcetylcysteine - a safe antidote for cysteine/glutathione deficiency. Curr Opin Pharmacol 7:355-9.
11. Balali-Mood M, Hefazi M. (2005). The pharmacology, toxicology, and medical treatment of sulphur mustard poisoning. Fundam Clin Pharmacol 19:297-315.
12. Bobb AJ, Arfsten DP, Jederberg WW. (2005). N-acetyl-L-cysteine as prophylaxis against sulfur mustard. Mil Med 170:52-6.
13. Bonanomi L, Gazzaniga A. (1980). Toxicological, pharmacokinetic and metabolic studies on acetylcysteine. Eur J Respir Dis Suppl 111: 45-51.
14. Childs A, Jacobs C, Kaminski T, et al. (2001). Supplementation with vitamin C and N-acetyl-cysteine increases oxidative stress in humans after an acute muscle injury induced by eccentric exercise. Free Radic Biol Med 31:745-53.
15. Cowan FM, Anderson DR, Broomfield CA, et al. (1997). Biochemical alterations in rat lung lavage fluid following acute sulfur: II. Increase in proteolytic activity. Inhal Toxicol 9:53-61.
16. Cowan FM, Broomfield CA, Smith WJ. (1992). Inhibition of sulfur mustard-increased protease activity by niacinamide, N-acetyl-L-cysteine or dexamethasone. Cell Biol Toxicol 8:129-38.
17. Dabrowska MI, Becks LL, Lelli Jr JL, et al. (1996). Sulfur mustard induces apoptosis and necrosis in endothelial cells. Toxicol Appl Pharmacol 141:568-83.
18. Das SK, Mukherjee S, Smith MG, Chatterjee D. (2003). Prophylactic protection by N-acetylcysteine against the pulmonary injury induced by 2-chloroethyl ethyl sulfide, a mustard analogue. J Biochem Mol Toxicol 17:177-84.
19. De Rosa SC, Zaretsky MD, Dubs JG, et al. (2000). N-acetylcysteine replenishes glutathione in HIV infection. Eur J Clin Invest 30:915-29.
20. Dekhuijzen PN. (2004). Antioxidant properties of N-acetylcysteine: their relevance in relation to chronic obstructive pulmonary disease. Eur Respir J 23:629-36.
21. Dodd S, Dean O, Copolov DL, et al. (2008). N-acetylcysteine for antioxidant therapy: pharmacology and clinical utility. Expert Opin Biol Ther 8:1955-62.
22. Emad A, Rezaian GR. (1997). The diversity of the effects of sulfur mustard gas inhalation on respiratory system 10 years after a single, heavy exposure: analysis of 197 cases. Chest 112:734-8.
23. Foroutan SA. (1997). Medical notes on the chemical warfare: Part II (in Persian). Kowsar Med J 1:159-77.
24. Gao X, Anderson DR, Brown AW, et al. (2011). Pathological studies on the protective effect of a macrolide antibiotic, roxithromycin, against sulfur mustard inhalation toxicity in a rat model. Toxicol Pathol 39: 1056-64.
25. Gao X, Ray R, Xiao Y, et al. (2007). Inhibition of sulfur mustard-induced cytotoxicity and inflammation by the macrolide antibiotic roxithromycin in human respiratory epithelial cells. BMC Cell Biol 8:17.
26. Gao X, Ray R, Xiao Y, et al. (2010). Macrolide antibiotics improve chemotactic and phagocytic capacity as well as reduce inflammation in sulfur mustard-exposed monocytes. Pulm Pharmacol Ther 23: 97-106.
27. Gao X, Ray R, Xiao Y, Ray P. (2008). Suppression of inducible nitric oxide synthase expression and nitric oxide production by macrolide antibiotics in sulfur mustard-exposed airway epithelial cells. Basic Clin Pharmacol Toxicol 103:255-61.
28. Ghabili K, Agutter PS, Ghanei M, et al. (2011). Sulfur mustard toxicity: history, chemistry, pharmacokinetics, and pharmacodynamics. Crit Rev Toxicol 41:384-403.
29. Ghanei M, Abolmaali K, Aslani J. (2004a). Efficacy of concomitant administration of clarithromycin and acetylcysteine in bronchiolitis obliterans in seventeen sulfur mustard-exposed patients: an open-label study. Curr Therapeut Res 65:495-504.
30. Ghanei M, Akhlaghpoor S, Moahammad MM, Aslani J. (2004b). Tracheobronchial stenosis following sulfur mustard inhalation. Inhal Toxicol 16:845-9.
31. Ghanei M, Ghasemzadeh M, Shohrati M. (2005a). Improvement of respiratory symptoms by long-term low-dose erythromycin in sulfur mustard exposed cases: a pilot study (in persian). J Med C B R Def 3: 1-9.
32. Ghanei M, Khalili AR, Arab MJ, et al. (2005b). Diagnostic and therapeutic value of short-term corticosteroid therapy in exacerbation of mustard gas-induced chronic bronchitis. Basic Clin Pharmacol Toxicol 97:302-5.
33. Ghanei M, Rajaeinejad M, Motiei-Langroudi R, et al. (2011). Helium:oxygen versus air:oxygen noninvasive positive-pressure ventilation in patients exposed to sulfur mustard. Heart Lung 40:e84-9.
34. Ghanei M, Shohrati M, Harandi AA, et al. (2007). Inhaled corticosteroids and long-acting beta 2-agonists in treatment of patients with chronic bronchiolitis following exposure to sulfur mustard. Inhal Toxicol 19:889-94.
35. Ghanei M, Shohrati M, Jafari M, et al. (2008). N-acetylcysteine improves the clinical conditions of mustard gas-exposed patients with normal pulmonary function test. Basic Clin Pharmacol Toxicol 103:428-32.
36. Grandjean EM, Berthet P, Ruffmann R, Leuenberger P. (2000). Efficacy of oral long-term N-acetylcysteine in chronic bronchopulmonary disease: a meta-analysis of published double-blind, placebo-controlled clinical trials. Clin Ther 22:209-21.
37. Grassi C, Morandini GC. (1976). A controlled trial of intermittent oral acetylcysteine in the long-term treatment of chronic bronchitis. Eur J Clin Pharmacol 9:393-6.
38. Gross CL, Innace JK, Hovatter RC, et al. (1993). Biochemical manipulation of intracellular glutathione levels influences cytotoxicity to isolated human lymphocytes by sulfur mustard. Cell Biol Toxicol 9: 259-67.
39. Heard KJ. (2008). Acetylcysteine for acetaminophen poisoning. N Engl J Med 359:285-92.
40. Hoesel LM, Flierl MA, Niederbichler AD, et al. (2008). Ability of antioxidant liposomes to prevent acute and progressive pulmonary injury. Antioxid Redox Signal 10:973-81.
41. Jafari M, Ghanei M. (2010). Evaluation of plasma, erythrocytes, and bronchoalveolar lavage fluid antioxidant defense system in sulfur mustard-injured patients. Clin Toxicol (Phila) 48:184-92.
42. Ji L, Liu R, Zhang XD, et al. (2010). N-Acetylcysteine attenuates phosgene-induced acute lung injury via up-regulation of Nrf2 expression. Inhal Toxicol 22:535-42.
43. Jones CM, Lawrence A, Wardman P, Burkitt MJ. (2003). Kinetics of superoxide scavenging by glutathione: an evaluation of its role in the removal of mitochondrial superoxide. Biochem Soc Trans 31: 1337-9.
44. Jugg B, Fairhall S, Smith A, et al. (2013). N-Acetyl-L-cysteine protects against inhaled sulfur mustard poisoning in the large swine. Clin Toxicol (Phila) 51:216-24.
45. Kasahara K, Kita E, Maeda K, et al. (2005). Macrolide resistance of Streptococcus pneumoniae isolated during long-term macrolide therapy: difference between erythromycin and clarithromycin. J Infect Chemother 11:112-14.
46. Kehe K, Balszuweit F, Emmler J, et al. (2008). Sulfur mustard research - strategies for the development of improved medical therapy. Eplasty 10:e32.
47. Korkmaz A, Kunak ZI, Paredes SD, et al. (2008). The use of melatonin to combat mustard toxicity. Neuro Endocrinol Lett 29:614-19.
48. Kumar O, Sugendran K, Vijayaraghavan R. (2001). Protective effect of various antioxidants on the toxicity of sulphur mustard administered to mice by inhalation or percutaneous routes. Chem Biol Interact 134: 1-12.
49. Lailey AF. (1997). Oral N-acetylcysteine protects against perfluoroisobutene toxicity in rats. Hum Exp Toxicol 16:212-16.
50. Lailey AF, Hill L, Lawston IW, et al. (1991). Protection by cysteine esters against chemically induced pulmonary oedema. Biochem Pharmacol 42:S47-54.
51. LaRowe SD, Mardikian P, Malcolm R, et al. (2006). Safety and tolerability of N-acetylcysteine in cocaine-dependent individuals. Am J Addict 15:105-10.
52. Liu J, Powell KL, Thames HD, MacLeod MC. (2010). Detoxication of sulfur half-mustards by nucleophilic scavengers: robust activity of thiopurines. Chem Res Toxicol 23:488-96.
53. Mardikian PN, LaRowe SD, Hedden S, et al. (2007). An open-label trial of N-acetylcysteine for the treatment of cocaine dependence: a pilot study. Prog Neuropsychopharmacol Biol Psychiatry 31:389-94.
54. McClintock SD, Hoesel LM, Das SK, et al. (2006). Attenuation of half sulfur mustard gas-induced acute lung injury in rats. J Appl Toxicol 26:126-31.
55. McClintock SD, Till GO, Smith MG, Ward PA. (2002). Protection from half-mustard-gas-induced acute lung injury in the rat. J Appl Toxicol 22:257-62.
56. Millea PJ. (2009). N-acetylcysteine: multiple clinical applications. Am Fam Physician 80:265-9.
57. Mirsadraee M, Attaran D, Boskabady MH, Towhidi M. (2005). Airway hyperresponsiveness to methacholine in chemical warfare victims. Respiration 72:523-8.
58. Mukherjee S, Stone WL, Yang H, et al. (2009). Protection of half sulfur mustard gas-induced lung injury in guinea pigs by antioxidant liposomes. J Biochem Mol Toxicol 23:143-53.
59. Mukhopadhyay S, Mukherjee S, Ray BK, et al. (2010). Antioxidant liposomes protect against CEES-induced lung injury by decreasing SAF-1/MAZ-mediated inflammation in the guinea pig lung. J Biochem Mol Toxicol 24:187-94.
60. Mukhopadhyay S, Mukherjee S, Stone WL, et al. (2009). Role of MAPK/AP-1 signaling pathway in the protection of CEES-induced lung injury by antioxidant liposome. Toxicology 261:143-51.
61. Mukhopadhyay S, Rajaratnam V, Mukherjee S, et al. (2006). Modulation of the expression of superoxide dismutase gene in lung injury by 2- chloroethyl ethyl sulfide, a mustard analog. J Biochem Mol Toxicol 20:142-9.
62. O'Neill HC, White CW, Veress LA, et al. (2010). Treatment with the catalytic metalloporphyrin AEOL 10150 reduces inflammation and oxidative stress due to inhalation of the sulfur mustard analog 2- chloroethyl ethyl sulfide. Free Radic Biol Med 48:1188-96.
63. Panahi Y, Ghanei M, Aslani J, Mojtahedzadeh M. (2005). The therapeutic effect of gamma interferon in chronic bronchiolitis due to mustard gas. Iran J Allergy Asthma Immunol 4:83-90.
64. Paromov V, Qui M, Yang H, et al. (2008). The influence of N-acetyl-Lcysteine on oxidative stress and nitric oxide synthesis in stimulated macrophages treated with a mustard gas analogue. BMC Cell Biol 9: 33.
65. Periti P, Mazzei T, Mini E, Novelli A. (1993). Adverse effects of macrolide antibacterials. Drug Saf 9:346-64.
66. Poole PJ, Black PN. (2001). Oral mucolytic drugs for exacerbations of chronic obstructive pulmonary disease: systematic review. BMJ 322: 1271-4.
67. Poole PJ, Black PN. (2003). Preventing exacerbations of chronic bronchitis and COPD: therapeutic potential of mucolytic agents. Am J Respir Med 2:367-70.
68. Poursaleh, Z, Harandi AA, Vahedi E, Ghanei M. (2012). Treatment for sulfur mustard lung injuries; new therapeutic approaches from acute to chronic phase. Daru 20:27.
69. Prescott L. (2005). Oral or intravenous N-acetylcysteine for acetaminophen poisoning? Ann Emerg Med 45:409-13.
70. Rahman I, MacNee W. (2012). Antioxidant pharmacological therapies for COPD. Curr Opin Pharmacol 12:256-65.
71. Rahman I. (2008). Antioxidant therapeutic advances in COPD. Ther Adv Respir Dis 2:351-74.
72. Rahman I. (2012). Pharmacological antioxidant strategies as therapeutic interventions for COPD. Biochim Biophys Acta 1822: 714-28.
73. Rappeneau S, Baeza-Squiban A, Marano F, Calvet J. (2000). Efficient protection of human bronchial epithelial cells against sulfur and nitrogen mustard cytotoxicity using drug combinations. Toxicol Sci 58:153-60.
74. Razavi SM, Salamati P, Harandi AA, Ghanei M. (2013). Prevention and treatment of respiratory consequences induced by sulfur mustard in Iranian casualties. Int J Prev Med 4:383-9.
75. Rowell M, Kehe K, Balszuweit F, Thiermann H. (2009). The chronic effects of sulfur mustard exposure. Toxicology 263:9-11.
76. Saber H, Saburi A, Ghanei M. (2012). Clinical and paraclinical guidelines for management of sulfur mustard induced bronchiolitis obliterans; from bench to bedside. Inhal Toxicol 24:900-6.
77. Saburi A, Ghanei M. (2013). Comments on ''Sulfur Mustard and Respiratory Diseases,'' Tang & Loke (2012) and a prepared integrated mechanism for chronic pulmonary disease from exposure to sulfur mustard. Crit Rev Toxicol 43:275-6.
78. Sadowska AM, Verbraecken J, Darquennes K, De Backer WA. (2006). Role of N-acetylcysteine in the management of COPD. Int J Chron Obstruct Pulmon Dis 1:425-34.
79. Sadowska AM. (2012). N-Acetylcysteine mucolysis in the management of chronic obstructive pulmonary disease. Ther Adv Respir Dis 6: 127-35.
80. Sandilands EA, Bateman DN. 2009. Adverse reactions associated with acetylcysteine. Clin Toxicol (Phila) 47:81-8.
81. Särnstrand B, Jansson AH, Matuseviciene G, et al. (1999). N,N0- Diacetyl-L-cystine-the disulfide dimer of N-acetylcysteine-is a potent modulator of contact sensitivity/delayed type hypersensitivity reactions in rodents. J Pharmacol Exp Ther 88:1174-84.
82. Sciuto AM, Strickland PT, Kennedy TP, Gurtner GH. (1995). Protective effects of N-acetylcysteine treatment after phosgene exposure in rabbits. Am J Respir Crit Care Med 151:768-72.
83. Shohrati M, Aslani J, Eshraghi M, et al. (2008a). Therapeutics effect of N-acetyl cysteine on mustard gas exposed patients: evaluating clinical aspect in patients with impaired pulmonary function test. Respir Med 102:443-8.
84. Shohrati M, Ghanei M, Shamspour N, et al. (2010). Glutathione and malondialdehyde levels in late pulmonary complications of sulfur mustard intoxication. Lung 188:77-83.
85. Shohrati M, Ghanei M, Shamspour N, Jafari M. (2008b). Activity and function in lung injuries due to sulphur mustard. Biomarkers 13: 728-33.
86. Stey C, Steurer J, Bachmann S, et al. (2000). The effect of oral Nacetylcysteine in chronic bronchitis: a quantitative systematic review. Eur Respir J 16:253-62.
87. Tamaoki J, Takeyama K, Tagaya E, Konno K. (1995). Effect of clarithromycin on sputum production and its rheological properties in chronic respiratory tract infections. Antimicrob Agents Chemother 39: 1688-90.
88. Tang FR, Loke WK. (2012). Sulfur mustard and respiratory diseases. Crit Rev Toxicol 42:688-702.
89. Tramper-Stranders GA, Wolfs TF, Fleer A, et al. (2007). Maintenance azithromycin treatment in pediatric patients with cystic fibrosis: longterm outcomes related to macrolide resistance and pulmonary function. Pediatr Infect Dis J 26:8-12.
90. Weinberger B, Laskin JD, Sunil VR, et al. (2011). Sulfur mustardinduced pulmonary injury: therapeutic approaches to mitigating toxicity. Pulm Pharmacol Ther 24:92-9.
91. Wilde PE, Upshall DG. (1994). Cysteine esters protect cultured rodent lung slices from sulphur mustard. Hum Exp Toxicol 13:743-8.
92. Yaren H, Mollaoglu H, Kurt B, et al. (2007). Lung toxicity of nitrogen mustard may be mediated by nitric oxide and peroxynitrite in rats. Res Vet Sci 83:116-22.